Viking Files 424B5 for $200M Common Stock Offering, Part of $400M Concurrent Raise
VKTX sits 55% above its 52-week low of $24.78 on elevated volume (5.0× avg).
Summary
Viking Therapeutics filed a preliminary prospectus supplement for a $200 million common stock offering, part of a $400 million concurrent raise that also includes $200 million in convertible notes. The offering follows positive Phase 2 VK2735 data and will fund continued clinical development. The common offering was later upsized to $275,000,005 and the notes to $225,000,000.
Updated with an SEC FWP filing · What changed
Updates
· SEC FWP — Common offering upsized to $275,000,005 (7,857,143 shares at $35.00), notes to $225,000,000 with 2.00% coupon, 45% conversion premium, initial conversion price $50.75.
Key Events · Financing and Capital Events · VKTX
-
Updated · · SEC FWP
Common Offering Upsized to $275,000,005, Notes to $225,000,000
Viking filed a preliminary 424B5 prospectus supplement for a $200 million common stock offering, part of a $400 million concurrent raise that also includes $200 million in convertible senior notes due 2032. The common offering was later upsized to $275,000,005, or 7,857,143 shares at $35.00 per share, and the notes were upsized to $225,000,000 with a 2.00% coupon, a 45% conversion premium, and an initial conversion price of $50.75.
-
Underwriters and Lock-Up Terms
Morgan Stanley and J.P. Morgan are joint book-running managers. The company and its directors/executive officers are subject to a 60-day lock-up period, and underwriters have a 30-day option to purchase additional shares.
-
Use of Proceeds
Net proceeds will fund continued clinical development of VK2735 and VK3019, plus general R&D, working capital, and corporate purposes.
-
Timing After Positive VK2735 Data
The offering comes one day after Viking reported positive Phase 2 maintenance data for VK2735 showing up to 97% weight loss maintenance with every-other-week dosing.
Analysis · VKTX · Life Sciences
Viking Therapeutics is formalizing a $200 million common stock offering as part of a $400 million concurrent capital raise that also includes $200 million in convertible senior notes due 2032. The offering comes just one day after the company reported positive Phase 2 maintenance data for VK2735, its lead obesity candidate, and follows a $500 million ATM program established in July 2026. The capital raise is substantial relative to the company's $4.86 billion market cap and will fund the continued clinical development of VK2735 and VK3019. The offering is being led by Morgan Stanley and J.P. Morgan, with a 60-day lock-up period for insiders and a 30-day underwriter option to purchase additional shares. The filing does not yet disclose the final offering price or number of shares, as it is a preliminary prospectus supplement. The common offering was later upsized to $275,000,005, or 7,857,143 shares at $35.00 per share, and the convertible notes were upsized to $225,000,000 with a 2.00% coupon, a 45% conversion premium, and an initial conversion price of $50.75.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VKTX was trading at $38.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $24.78 to $43.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.